Cemiplimab and Metronomic Chemotherapy in Recurrent/Metastatic (R/M) Squamous Cell Carcinoma (SCC) of the Head and Neck (H & N): Trial in Progress.

The current first-line standard of care for recurrent/metastatic head and neck (H&N) squamous cell carcinoma (SCC) is anti-programmed death-ligand 1 (anti-PD-L1) immune checkpoint inhibition. Metronomic chemotherapy, low-dose high-frequency dosage aims to enhance immunomodulation, inhibit angiogenesis, and mitigate chemotherapy-related complications.

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: F. Rind, P. Bhateja, C. Verschraegen, N. Seim, S. Baliga, E. Gogineni, D.J. Konieczkowski, M. Old, J.W. Rocco, D.M. Blakaj, M. Bonomi Tags: 154 Source Type: research